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The pyrimidine analogue gemcitabine is an established effective agent in the treatment of non-small-cell lung cancer (NSCLC). The
present study investigates whether gemcitabine would be synergistic with the topoisomerase I inhibitor topotecan against the NSCLC
A549 and Calu-6 cells. Cells were treated with gemcitabine and topotecan for 1h and the type of drug interaction was assessed using
the combination index (CI). Cell cycle alterations were analysed by flow cytometry, while apoptosis was examined by the occurrence
of DNA internucleosomal fragmentation, nuclear condensation and caspase-3 activation. Moreover, the possible involvement of the
PI3K-Akt signalling pathway was investigated by the measurement of Akt phosphorylation. Finally, quantitative, real-time PCR (QRT-
PCR) was used to study modulation of the gemcitabine-activating enzyme deoxycytidine kinase (dCK) and the cellular target enzyme
ribonucleotide reductase (RR). In results, it was found that simultaneous and sequential topotecan-gemcitabine treatments were
synergistic, while the reverse sequence was antagonistic in both cell lines. DNA fragmentation, nuclear condensation and enhanced
caspase-3 activity demonstrated that the drug combination markedly increased apoptosis in comparison with either single agent,
while cell cycle analysis showed that topotecan increased cells in S phase. Furthermore, topotecan treatment significantly decreased
the amount of the activated form of Akt, and enhanced the expression of dCK (þ155.0 and þ115.3% in A549 and Calu-6 cells,
respectively), potentially facilitating gemcitabine activity. In conclusion, these results indicate that the combination of gemcitabine and
topotecan displays schedule-dependent activity in vitro against NSCLC cells. The gemcitabine-topotecan sequence is antagonistic
while drug synergism is obtained with the simultaneous and the sequential topotecan-gemcitabine combinations, which are
associated with induction of decreased Akt phosphorylation and increased dCK expression.
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Despite recent advances in early diagnosis and treatment, non-
small-cell lung cancer (NSCLC) is a disease with severe prognosis.
The majority of patients with NSCLC are administered chemother-
apy (Bunn and Kelly, 1998; Arriagada et al, 2004); however, the
efficacy of cytotoxic drugs is still unsatisfactory, with a low
percentage of complete remissions and short duration of clinical
response. The NSCLC Collaborative Group (1995) meta-analysis
study revealed a survival benefit of 10% at 1 year in a supportive
care setting and an increased median survival of 6 weeks in
patients treated with platinum-based chemotherapy, thus empha-
sising the need for new effective drugs and combination regimens.
Clinical studies have shown that a number of new chemother-
apeutic agents, such as gemcitabine, topoisomerase I inhibitors,
taxanes and vinca alkaloids, are active agents in NSCLC (Bunn and
Kelly, 1998). Preclinical studies with gemcitabine and etoposide
(van Moorsel et al, 1999a,b), gemcitabine and carboplatin or
paclitaxel (Edelman et al, 2001), and topotecan and cisplatin
(Kaufmann et al, 1996) have shown schedule-dependent drug
interactions in several human lung cancer cell lines.
Results from clinical studies suggested that the combination of
gemcitabine and topotecan compared favourably with others
regimens accepted as reasonable treatment for NSCLC, and that
further investigations of this combination is recommended
(Dowlati and Levitan, 2003). A phase II trial of topotecan and
gemcitabine in 35 patients with previously treated advanced
NSCLC, of whom 17 had not responded to first-line therapy,
demonstrated antitumour activity, with 11% partial responses and
23% stable diseases, a 1-year survival rate of 20% and a
manageable toxicity profile (Rinaldi et al, 2002). In another phase
I/II trial, based on preclinical data showing synergism against A549
cells, the combination of topotecan and gemcitabine was
administered to 24 patients with previously untreated metastatic
or unresectable NSCLC, and seemed to be active, with 21% partial
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sresponses and acceptable haematologic toxicity (Dabrow et al,
2003). Finally, a phase II multicentre study of combined topotecan
and gemcitabine as first-line chemotherapy in 51 patients with
advanced NSCLC showed a 1-year survival (39%) similar to
platinum-based regimens, with 17% partial responses, a high
percentage of patients achieving stable disease (23%) and no
significant toxicities (Joppert et al, 2003).
Gemcitabine (dFdC, 20,20-difluoro-20-deoxycytidine) is a
deoxycytidine analogue with a broad spectrum of anticancer
activity against several solid tumours in preclinical models
(van Moorsel et al, 2000), and it is now an established effective
agent in the treatment of NSCLC and pancreatic cancer (Noble and
Goa, 1997). Gemcitabine is assumed to exert its antitumour
effect mainly by incorporation of its triphosphate metabolite
(dFdCTP) into DNA, after which DNA polymerase adds one
additional deoxynucleotide and DNA synthesis is interrupted.
The rate-limiting step in the activation of the drug is catalysed
by deoxycytidine kinase (dCK), which is a limiting factor
for the cytotoxic activity of gemcitabine. Furthermore, the
diphosphate metabolite (dFdCDP) inhibits ribonucleotide
reductase (RR), an enzyme that converts ribonucleotides to
deoxyribonucleotides, required for DNA polymerisation and
repair. Ribonucleotide reductase consists of dimerised large
and small subunits 1 and 2 (RRM1 and RRM2), whose pairing
is essential for scheduled DNA synthesis to occur. The interaction
between gemcitabine and RR has not been well characterised;
however, data support the hypothesis that the RRM1 subunit is
the most important intracellular target of dFdCDP (van der Donk
et al, 1998), although resistance to gemcitabine was observed
both in RRM1- and RRM2-overexpressing cells (Goan et al,
1999; Davidson et al, 2004). Thus, gemcitabine resistance
may be dependent on decreased expression of dCK, or over-
expression of RR.
Topotecan is a water-soluble camptothecin derivative, which
forms a stable, cleavable complex with the DNA-topoisomerase I.
This process leads to breaks in the DNA strand resulting in
apoptosis and cell death (Kollmannsberger et al, 1999). Recent
studies demonstrated that topotecan exhibited its cytotoxic effects
also by downregulating the PI3K-Akt signalling pathway, which is
involved in prevention of apoptosis (Nakashio et al, 2002).
Gemcitabine and topotecan have different mechanisms of
action, partially nonoverlapping toxicities and both drugs are
active on tumour cells in the S-phase of the cell cycle (Tolis et al,
1999). Furthermore, the anti-topoisomerase I activity of topotecan
might impair the excision-repair mechanisms of DNA and could
potentiate the activity of gemcitabine, mainly by enhancement of
apoptosis (Nakashio et al, 2000). Finally, selection of drugs to be
combined with gemcitabine should be performed on the basis of
their ability to modulate gene expression of critical enzymes dCK
and RR (Bergman et al, 2002).
The purpose of the present study was to assess the efficacy of
gemcitabine and topotecan combinations against NSCLC in vitro,
studying several mechanisms involved in drug interaction, in order
to provide experimental data in support of their clinical use in
NSCLC.
MATERIALS AND METHODS
Drugs and chemicals
Topotecan and gemcitabine were generous gifts from Glaxo-
SmithKline (King of Prussia, PA, USA) and Eli Lilly Company
(Indianapolis, IN, USA), respectively. Drugs were dissolved in
sterile distilled water and diluted in culture medium immediately
before use.
RPMI medium, fetal bovine serum (FBS), L-glutamine (2mM),
penicillin (50IUml
 1), streptomycin (50mgml
 1), agarose and
DNA ladder were from Gibco (Gaithersburg, MD, USA). All
other chemicals were from Sigma Chemical Co. (St Louis, MO,
USA).
Cell culture
The NSCLC cell lines A549 (adenocarcinoma) and Calu-6
(epidermoid carcinoma) were from ATCC (Manassas, VA, USA)
and were cultured, respectively, in RPMI and MEM (90%),
supplemented with FBS (10%), L-glutamine (1%) and penicillin–
streptomycin (1%), in an atmosphere of 5% CO2 at 371C. Cells
were routinely grown in 75cm
2 tissue culture flasks (Costar,
Cambridge, MA, USA) and were harvested with a solution of
trypsin–EDTA when they were in logarithmic phase of growth,
and maintained at the above-described culture conditions for all
experiments.
Assay of cytotoxicity
Cells were harvested from cultures and plated in six-well sterile
plastic plates (Costar, Cambridge, MA, USA) at 10
4cellswell
 1, and
allowed to attach for 24h. Cells were treated as follows: (1)
gemcitabine (0.1–10
5ngml
 1) for 1h; (2) topotecan (0.1–
10
5ngml
 1) for 1h; (3) topotecan for 1h followed by medium
change and then gemcitabine for 1 additional hour; (4) the reverse
sequence of point (3) above and (5) simultaneous treatment
(topotecan and gemcitabine for 1h). After treatment, cells were
cultured in drug-free medium and the growth inhibition by drugs
was assessed by counting cells surviving after 72h. Cell
cytotoxicity was expressed as the percentage of control cell
number, and the 50% inhibitory concentration of cell growth
(IC50) was calculated by nonlinear least-squares curve fitting
(GraphPad PRISM; Intuitive Software for Science, San Diego, CA,
USA).
The type of drug interaction between gemcitabine and topotecan
was assessed at a fixed concentration ratio of topotecan:gemci-
tabine, by using the combination index (CI) of Chou et al (1994).
The data were processed by the Calcusyn software (Biosoft;
Oxford, UK).
Cell cycle analysis
Cell cycle alterations induced by treatments were studied by flow
cytometry analysis. Cells were plated at a density of 1 10
6 in
100-mm Petri dishes (Costar, Cambridge, MA, USA) and allowed
to attach for 24h. After single drug treatments with gemcitabine or
topotecan at IC50 concentration levels, cells were collected by
trypsinisation and washed twice with PBS. DNA staining was
performed with a solution containing RNase (1mgml
 1), Nonidet
(0.1%) and propidium iodide (25mgml
 1) and the samples were
stored on ice for 30min. Analysis was performed using a FACScan
(Becton Dickinson, San Jose, CA, USA) and data analysis was
carried out with CELLQuest software, while cell cycle distribution
was determined using Modfit software (Verity Software House,
Inc., Topsham, ME, USA).
Analysis of apoptosis by DNA fragmentation
Tumour cells (2 10
6) were plated in 100mm sterile dishes and
treated with IC50 concentrations of drugs for 1h. At the end of
treatment, detection of apoptosis was performed as described
previously (Danesi et al, 1996). Cells were lysed and treated with
proteinase K. The DNA was precipitated with NaCl, ethanol and
glycogen, dried, resuspended in Tris/EDTA, containing bovine
pancreatic ribonuclease A and electrophoresed on a 1% agarose gel
at 90mV for 60min. Bands were visualised using ethidium
bromide staining, compared against a 180 DNA ladder for
fragment size identification, and gels were photographed with a
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sPolaroid MP4 Land Camera (Polaroid, Cambridge, MA, USA). Film
densities of apoptosis assays were quantified through video
imaging densitometry with the KS300 version 1.2 software
(Kontron Elektronic, Eching, Germany).
Analysis of apoptosis by nuclear staining
Gemcitabine, topotecan and their combinations were also char-
acterised for their ability to induce nuclear condensation and
fragmentation, as detected by bisbenzimide staining. Briefly, cells
were treated as described above for DNA fragmentation analysis; at
the end of incubation, cells were washed twice with PBS, fixed in
4% neutral-buffered paraformaldehyde, and incubated at room
temperature for 15min. Cells were then resuspended in a solution
containing bisbenzimide trihydrochloride 8mgml
 1 and incubated
for 15min at room temperature. The cell suspensions were spotted
on sylanised microscope glass slides and examined by fluorescence
microscopy (Leica, Germany) for the presence of chromatin
condensation and nuclear fragmentation. A total of 200 cells from
randomly chosen microscopic fields were counted in a blinded
fashion, and the apoptotic index was calculated as the percentage
ratio between the number of cells displaying apoptotic appearance
and the total number of counted cells.
Assay of caspase-3 activity
To assess whether caspase-3 is activated upon treatment with
gemcitabine or topotecan, enzyme activity was measured by the
caspase-3 assay kit (Calbiochem, Oxford, UK). Cells were treated as
described above for apoptosis analysis. At the end of incubation,
cells were washed twice with PBS, harvested by centrifugation
(1000g for 10min at 41C), and resuspended in 50mlo fl y s i sb u f f e r
(HEPES 50nM, DTT 10mM,E D T A0 . 1 m M, CHAPS 0.1% and
Nonidet P-40 0.1%) at 41C for 15min. The cell lysate was centrifuged
at 10000g for 10min at 41C, and the supernatants, representing
cytoplasmatic extracts, were transferred to a microtitre plate and
mixed with assay buffer (HEPES 50nM, DTT 10mM, glycerol 10%
and CHAPS 0.1%, pH 7.4) added to each well. The reaction was
started by adding 10ml of caspase-3 colorimetric substrate (Ac-
DEVD-pNA); controls were obtained with the caspase-3 inhibitor
Ac-DEVD-CHO, to measure nonspecific hydrolysis of the substrate,
and with the human recombinant caspase-3, to compare the activity
of a known amount of enzyme with the caspase-3 activity in cells
extracts. Plates were then incubated at 371C for 10min, after which
the absorbance was read at 405nm. A microtitre-plate reader
conversion factor was then calculated, taking into account the
concentration of p-nitroaniline in the calibration standard, and the
activity of caspase-3 (pmol substratemin
 1)i nt h es a m p l e sw a s
obtained as the slope of the curve conversion factor. Finally,
enzyme activity was normalised with respect to total protein content
of each cell extract, as measured with the Lowry reagent, and
expressed as pmolmin
 1 mg protein
 1.
Assay of Akt phosphorylation
Akt protein activation by phosphorylation after gemcitabine or
topotecan treatment was assayed with a P-Ser473-specific ELISA
(BioSource International, Camarillo, CA, USA) and normalised to
the total Akt content (BioSource). Cells were treated as described
above for apoptosis analysis. At the end of incubation, cells were
washed twice with PBS, harvested by centrifugation (1000g for
5min at 41C), and resuspended in 25ml of extraction buffer
(BioSource) for 30min on ice, while vortexing as per protocol
directions. A volume of 5ml of cell extract was diluted to 100mli n
sodium azide (NaN3 15mM), centrifuged at 15000g for 10min at
41C and transferred to ELISA microtitre wells, coated with a
monoclonal antibody specific for total Akt. A standard curve was
run with each assay using 100, 50, 25, 12.5, 6.25, 3.12 and
1.6Uml
 1 of phosphorylated full-length human recombinant Akt
(Akt P-Ser473) and 20, 10, 5, 2.5, 1.25, 0.6 and 0.3ngml
 1 of
human recombinant total Akt. After overnight incubation at 41C,
the solution was aspirated from wells and 100ml of rabbit anti-Akt
P-Ser473 and biotin-conjugated anti-total Akt were added into
each well of Akt P-Ser473 and total Akt, respectively. Plates were
incubated at room temperature for 1h, washed four times and
100ml of a working solution of a horseradish peroxidase-labelled
anti-rabbit IgG and horseradish peroxidase-labelled streptavidin
was added into each well of Akt P-Ser473 and total Akt ELISA
assay, respectively. After 30min, a chromogen solution was added;
20min later, the reactions were stopped with 100ml of a stop
solution and the absorbance was read at 450nm. To calculate Akt
P-Ser473 and total Akt concentrations, a standard curve method
was used (Figure 1). Values of P-Ser473 calculated from the
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Figure 1 P-Ser473 Akt and Akt total standard curves for validation of P-
Ser473-Akt activity ELISA assays. The following equations apply to the P-
Ser473 Akt and Akt total concentrations: y¼4.628x/(25.39þx), R
2¼0.99
(P-Ser473 Akt); and y¼8.116x/(29.91þx), R
2¼0.99 (Akt total).
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contents.
Quantitative, real-time PCR analysis
In order to assess the effect of treatments on expression of the key
enzymes dCK and RR, total cellular RNA was extracted from cells
treated as described above for cell cycle analysis, using TRI
REAGENT LS (Sigma). RNA was dissolved in 10mmoll
 1 DTT and
200Uml
 1 RNase inhibitor in RNase free-water, and measured at
260nm. RNA (1mg) was reverse transcribed at 371C for 1h in a
100-ml reaction volume containing 0.8mM deoxynucleotide mix
(dNTPs), 200U of Moloney murine leukemia virus reverse
transcriptase (MMLV-RT), 40U of RNase inhibitor and
0.05mgml
 1 random primers. The resulting cDNA was diluited
(2:3) and then amplified by QRT-PCR with the Applied
Biosystems 7900HT sequence detection system (Applied Biosys-
tems, Foster City, CA, USA). Quantitative, real-time PCR reactions
were performed in triplicate using 5ml of cDNA, 12.5ml of TaqMan
Universal PCR Master Mix, 2.5ml of the specific probe and 2.5mlo f
the forward and reverse specific primers in a total volume of 25ml.
PCR thermal cycling conditions, design and optimisation of primer
concentrations were reported in detail by Giovannetti et al (2004).
Amplifications were normalised to glyceraldehyde 3-phosphate
dehydrogenase (GAPDH), and the quantitation of gene expression
was performed using the DDCt calculation, where Ct is the
threshold cycle; the amount of target, normalised to the
endogenous control and relative to the calibrator (untreated
control cells), is given as 2 DDCt.
Statistical analysis
All experiments were performed in triplicate and repeated at least
three times. Data were expressed as mean values7s.e., and were
analysed by Student’s t-test or ANOVA followed by the Tukey’s
multiple comparison; the level of significance was set at Po0.05.
RESULTS
Cytotoxicity of gemcitabine and topotecan
A dose-dependent inhibition of cell growth was observed with
gemcitabine and topotecan, with IC50s of 131.2 and 840.2ngml
 1
(A549 cells) and 1662.4 and 562.3ngml
 1 (Calu-6 cells),
respectively. Following on from this, because the CI method
recommends a ratio of IC50s values that the drugs are equipotent,
combination studies were performed at fixed 6:1 and 1:3
(topotecan:gemcitabine) concentration ratios in A549 and
Calu-6 cells, respectively. These studies showed that the sequential
exposure of A549 cells to topotecan followed by gemcitabine
reduced the IC50 of gemcitabine to 12.4ngml
 1, while the
IC50 of gemcitabine resulting from the simultaneous combination
of drugs was 6.3ngml
 1 (Table 1). The cytotoxic activity of
gemcitabine was impaired when the drug was followed by
topotecan (IC50, 620.1ngml
 1). Similar results were obtained in
Calu-6 cells, with IC50s of 179.5, 40.4 and 2063.8ngml
 1 after
sequential topotecan-gemcitabine treatment, simultaneous com-
bination and the gemcitabine-topotecan schedule. The calcula-
tion of the CI demonstrated that while the gemcitabine-
topotecan sequential exposure showed antagonism at effect level
460%, the simultaneous and the topotecan-gemcitabine combi-
nation showed synergism at effect levels 450% inhibition, and the
degree of synergism observed with the simultaneous administra-
tion of topotecan and gemcitabine was considerably greater in
both cell lines (Figure 2).
Cell cycle effects of gemcitabine and topotecan
Both topotecan and gemcitabine were able to affect the cell cycle of
lung cancer cells (Table 2). In particular, after 1h treatment,
topotecan markedly increased the percentage of cells in the S phase
in A549 cells, from 39.6 to 64.9%, while there was a minimal
enhancement (þ6.1%) in Calu-6 cells. In contrast, flow cytometric
studies demonstrated that gemcitabine blocked cells in the G1-S
boundary. In particular, in Calu-6 cells, gemcitabine caused a 1.3-
fold increase in the population of cells in the G1 phase, from 50.5
to 64.1% (Figure 3), while DNA contents of cells treated with
gemcitabine showed a minimal increase (þ5.8%) at the G1–S
region in A549 cells (Figure 3).
Induction of apoptosis by gemcitabine and topotecan
The extent of DNA fragmentation was dependent on drug
treatment. In particular, the production of chromatin fragments
was clearly detectable after exposure to gemcitabine, topotecan
and all the combinations in both cell lines, while no substantial
Table 1 Effects of gemcitabine, topotecan or their combinations on cell proliferation, caspase activity and apoptosis in A549 and Calu-6 cells. Data are the
mean7s.e. from three independent experiments
Treatment Cells IC50 (ngml
 1)
a Apoptotic index
b Caspase activity (pmolmin
 1mg
 1)
c
Control A549 / 4.370.6% 0.1270.08
Calu-6 / 3.170.3% 0.1070.06
Topotecan A549 840.27121.2 7.771.4% 0.3270.11
Calu-6 562.3793.5 6.170.4% 0.3970.13
Gemcitabine A549 131.2730.3 13.474.6% 0.8670.14
Calu-6 1662.47360.6 8.672.0 0.6970.25
Gemcitabine-topotecan A549 620.17104.1 10.570.7% 1.0770.12
Calu-6 2063.87414.6 11.572.8% 0.9470.31
Gemcitabine+topotecan A549 12.471.4 34.073.6% 2.7670.10
Calu-6 40.474.76 27.673.6% 2.5570.37
Topotecan-gemcitabine A549 6.370.3 29.275.9% 1.4370.11
Calu-6 179.5738.7 19.873.2% 1.5570.28
a50% inhibitory concentrations of cell growth.
bPercentage ratio between the number of cells displaying apoptotic appearance and the total number of counted cells.
cEnzyme
activity is normalised with respect to total protein content of each cell extract.
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samount of internucleosomal DNA fragmentation was observed in
control samples (Figure 4). As shown in Figure 4, cells exposed to
topotecan–gemcitabine combination presented typical apoptotic
morphology with cell shrinkage, nuclear condensation and
fragmentation, and rupture of cells into debris. Analysis of
apoptosis by using bisbenzimide nuclear staining showed that
the occurrence of apoptotic cells was significantly higher (Po0.05)
after treatment with gemcitabine and topotecan (13.474.6 and
7.771.4%, respectively, vs controls, 4.370.6%, in A549 cells; and
8.672.0 and 6.170.4% vs 3.170.3% in Calu-6 cells). In the drug
combinations, the simultaneous administration of gemcitabine
and topotecan produced the highest apoptotic index either in A549
(34.073.6%) or in Calu-6 cells (27.673.6%), while the sequence
topotecan-gemcitabine was more effective than the reverse
sequence (Table 1).
Activation of caspase-3 by gemcitabine and topotecan
Drug treatments were able to significantly increase the activity of
caspase-3 over controls (0.1270. 08 and 0.1070.06
pmolmin
 1mg
 1 of protein in A549 and Calu-6 cells, respectively)
(Table 1). In A549 cells, caspase-3 activities values were 0.8670.14,
0.3270.11 and 1.0770.12pmolmin
 1mg
 1 of protein, respec-
tively, for gemcitabine, topotecan and the gemcitabine-topotecan
sequence, while the simultaneous and the topotecan-gemcitabine
sequence determined the maximum increase in caspase-3 activity,
2.7670.10 and 1.4370.11pmolmin
 1mg
 1 of protein, respec-
tively, vs untreated cells. Similar results were obtained in Calu-6
cells, with caspase-3 activities of 0.6970.25, 0.3970.13, 0.9470.31,
2.5570.37 and 1.5570.28pmolmin
 1mg
 1, after gemcitabine,
topotecan, gemcitabine-topotecan, gemcitabineþtopotecan or
topotecan-gemcitabine treatments (Table 1).
Inhibition of Akt phosphorylation
Both topotecan and gemcitabine were able to significantly reduce
the amount of phosphorylated Akt in A549 and Calu-6
cells (Po0.05). Although drug treatments had no effect on
total Akt protein expression, the amount of the phosphorylated
form of Akt was decreased up to 27.1% (A549 cells) and 50.7%
(Calu-6 cells) by topotecan and to 41.7% (A549 cells) and
34.7% (Calu-6 cells) by gemcitabine, in comparison with controls
(Figure 5).
Quantitative, real-time PCR analysis
Quantitative, real-time PCR analysis was performed to assess
whether the expression of dCK and RR was modulated by
topotecan and gemcitabine, at IC50 levels. The results are given
in Figure 6 and showed that both drugs significantly enhanced dCK
expression, up to 155.0 and 115.3%, after topotecan treatment and
87.3 and 83.3% after gemcitabine exposure, respectively, in A549
and Calu-6 cells (Po0.05), while there was only a slight increase in
RRM1 expression (þ38.7% in A549 and þ63.5% in Calu-6 cells)
after gemcitabine treatment.
DISCUSSION
Several studies reported that gemcitabine showed synergism
or additivity when combined with topotecan, cisplatin and
etoposide in various NSCLC cell lines (Tolis et al, 1999;
van Moorsel et al, 1999a,b), while topotecan demonstrated
synergism with etoposide in the NCI-H23 NSCLC cell line
(Taron et al, 2000). The combination of gemcitabine and topotecan
Topotecan → gemcitabine
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Figure 2 Combination index plots of topotecan–gemcitabine combina-
tion in A549 (A) and Calu-6 (B) cells. The most pronounced synergism
(CIo1) was demonstrated when the two drugs were combined
simultaneously in both cell lines.
Table 2 Cell cycle perturbation (%) induced by gemcitabine and
topotecan. Data represent mean percentage from three independent
experiments
Cells Treatment G1 (%) S (%) G2 (%)
A549 Control 46.06 39.58 14.36
Gemcitabine 51.91 33.45 14.64
Topotecan 33.42 64.89 1.69
Calu-6 Control 50.46 35.01 14.54
Gemcitabine 64.10 31.62 4.27
Topotecan 45.91 41.08 13.01
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recent study showed an additive cytotoxicity of gemcitabine
followed by topotecan in H460 and H322 NSCLC cell lines
(Tolis et al, 1999), while in A2780 ovarian cancer cells the same
combination showed antagonism (Distefano et al, 2000). In vitro
experimental findings reported in this study indicate that
topotecan and gemcitabine administered simultaneously and in
the sequence topotecan followed by gemcitabine were synergistic
against A549 and Calu-6 cell lines, while the reverse sequence was
antagonistic.
Recent studies have shown the importance of modulating the
cell cycle to exploit the effect of drug combinations (Shah
and Schwartz, 2001). In the present study, flow cytometry
demonstrated that topotecan caused an accumulation of cells in
the S phase. This finding is in agreement with previous data
on increased proportion of NSCLC cells in S and G2/M phases after
a 4-h exposure to topotecan (Tolis et al, 1999). As gemcitabine
is a S-phase specific drug, the increase in its activity
in the schedule topotecan-gemcitabine may be the result of
modulation of cell cycle, potentially facilitating dFdCTP
incorporation in DNA. Furthermore, the simultaneous use of
gemcitabine and topotecan enhanced apoptosis, as demonstrated
by the typical cellular morphology and the internucleosomal
DNA fragmentation. There is substantial evidence that gemcitabine
triggers apoptosis in human leukaemia and solid tumour
cells, including NSCLC cell lines (Pace et al, 2000) and the
concentration of gemcitabine required for this effect is similar to
the serum levels achieved in clinical trials (Hui and Reitz, 1997).
Triggering of the apoptotic machinery in response to a variety of
cellular stresses and physiological stimuli culminates in the
activation of caspases, resulting in cell death. Caspase-3 is
the most widely studied enzyme with respect to the cleavage of
target proteins (Fraser and Evan, 1996), and caspase-3-like
protease is involved in the apoptotic death of A549 cells
(Leech et al, 2000). Recent studies showed that treatment with
gemcitabine triggers caspase-3 activity in A549 cells (Lawrence
et al, 2001) and topoisomerase I is a substrate cleaved by caspase-3
(Samejima et al, 1999). Moreover, short exposures to camptothecin
(e.g., 1h) induce a dramatic decrease in topoisomerase I levels,
resulting in a reduction of protein-linked DNA strand breaks.
Therefore, the use of such agent simultaneously with other
compounds, compared with the sequential administration of the
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Figure 3 Histograms of DNA content of A549 (A–C) and Calu-6 (D–F) cells demonstrating the accumulation of cells in the S phase after topotecan
treatment (B and E), and the minimal increase in the G1 phase after gemcitabine exposure (C and F) with respect to controls (A and D).
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ssame agents, would result in different cytotoxic effects (Fu et al,
1999). In agreement with these findings, in vitro experimental data
obtained in this study indicate that gemcitabine significantly
increase the activity of caspase-3 over control. Although a
contradictory picture has emerged from previous studies on
topoisomerase I degradation and loss of activity during apoptotic
execution (Casiano et al, 1998), it might be possible that the
caspase-3 activation caused by the initial gemcitabine exposure
results in reduction of topoisomerase I, thus providing a possible
explanation for the antagonism of the gemcitabine-topotecan
sequence. On the other hand, in the reverse sequence and in the
simultaneous drug treatment, the prevalence of proapoptotic
mechanisms determined synergism. In particular, a recent study
showed that the reduction of phosphorylated PKB/Akt levels
correlated with the enhancement of gemcitabine-induced apopto-
sis and antitumour activity, suggesting that the PI3K-Akt pathway
plays a significant role in mediating drug sensitivity in human
123456L
Control Treated
Figure 4 DNA fragmentation in A549 cells after treatment with
gemcitabine (lane 4), gemcitabine and topotecan simultaneously (lane 1),
topotecan followed by gemcitabine (lane 2), gemcitabine followed by
topotecan (lane 3) and topotecan (lane 5) (above). The simultaneous
combination of topotecan and gemcitabine at the 6:1 fixed concentration
ratio determined the highest increase in apoptosis vs control (lane 6). L,
180 DNA ladder for fragment size identification. Nuclear staining of A549
cells exposed to gemcitabine–topotecan simultaneously. The typical
apoptotic morphology includes nuclear condensation, cell shrinkage and
formation of apoptotic bodies as compared to control cells (below).
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Figure 5 PI3-Akt-specific activity in drug-treated cells. The administra-
tion of gemcitabine and topotecan in A549 (A) and Calu-6 (B) cells
determined a significant reduction of phosphorylated form (normalised to
total Akt and protein content) vs control. Columns represent the data and
bars the s.e. of values obtained from three independent experiments.
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scancer cells (Ng et al, 2000). In agreement with previous data on
A549 cell line (Nakashio et al, 2000), this study demonstrated that
topotecan decreased the amount of the activated form of Akt both
in A549 and Calu-6 cells, so that it may improve the therapeutic
potential of gemcitabine by increasing apoptosis when it is
administered before or simultaneously.
The data of the present study also demonstrated for the
first time that gemcitabine and, more effectively, topotecan
increased the expression of dCK, potentially facilitating gemcita-
bine activation, while RR gene expression was not significantly
modulated by topotecan in both cell lines. There are
many observations suggesting that dCK is a limiting factor
for the cytotoxic activity of gemcitabine. Several cell lines,
which lack dCK activity, are resistant to nucleoside analogues
such as cytarabine or gemcitabine (Bergman et al, 1999, 2002),
and the sensitivity to nucleoside analoguess could be restored by
transfection of a wild-type dCK cDNA (Stegmann et al, 1995).
An increase in dCK expression was also observed after gemcitabine
exposure in pancreatic cancer PANC-1 and Capan-1 cells
(Giovannetti et al, 2004), suggesting that treatment with inhibitors
of DNA synthesis could potentiate the dCK expression of
various cells, because the salvage pathway initiated by
dCK accounts for the majority of nucleotide synthesis for DNA
repair. Other studies indicated that drugs that inhibit DNA
biosynthesis widely differ in their stimulatory effect on
dCK, and there are also ‘responsive’ and ‘nonresponsive’ cells
with respect to dCK activation (Spasokoukotskaja et al, 1999).
Thus, enhancement of the dCK activity by specific drugs
in ‘responsive’ cells may give a rationale for combination
chemotherapy.
Another hypothesis to explain the present results is that
DNA repair is inhibited by topotecan, thereby resulting in
increased gemcitabine incorporation into DNA. Indeed,
Bergman et al (1996) reported that the synergism between
gemcitabine and cisplatin appears to be mainly dependent on
an increase in platinum-DNA adduct formation possibly related to
changes in DNA caused by gemcitabine incorporation in DNA.
Theoretically, the topoisomerase I-dependent strand breaks
stabilised by topotecan offer sites for the insertion of gemcitabine
during DNA duplication. Finally, a recent study showed that
gemcitabine incorporation in cellular DNA enhanced the fre-
quency of collisions between the stabilised topoisomerase I
cleavage complex and transcription complexes, leading to
accumulation of strand breaks and ultimately to enhanced cell
death (Pourquier et al, 2002).
In conclusion, all these factors may contribute to the synergistic
effect of topotecan and gemcitabine in NSCLC cell lines and
provide the experimental basis for further clinical testing of these
drug combination for the treatment of NSCLC.
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